In patients with stage II–IIIA NSCLC whose tumors expressed PD-L1 TC ≥1%, 35% (88/248) of patients receiving atezolizumab and 46% (105/228) of patients receiving best supportive care experienced disease progression, indicating that adjuvant atezolizumab could reduce the risk of recurrence by 34% (HR=0.66; 95% CI: 0.50–0.88). Here, CD274 is linked to non-small cell lung carcinoma.